Paget's disease of the breast differential diagnosis: Difference between revisions
Preeti Singh (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) No edit summary |
||
Line 24: | Line 24: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
! rowspan="5" | | ! rowspan="5" |Benign or Malignant | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
! colspan="8" |Clinical manifestations | ! colspan="8" |Clinical manifestations | ||
! colspan=" | ! colspan="2" rowspan="2" |Para-clinical findings | ||
| rowspan="5" |Gold Standard | |||
| colspan="2" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Associated factors''' | | colspan="2" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Associated factors''' | ||
|- | |- | ||
! colspan=" | ! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ||
! colspan=" | ! colspan="2" rowspan="2" |Physical examination | ||
|- | |- | ||
! | !Lab Findings | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
! colspan=" | ! colspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Itching | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Itching | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mastalgia | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE | ||
|- | |- | ||
Line 50: | Line 47: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | !Nipple | ||
DIscharge | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Erythema | |||
|- | |- | ||
! rowspan=" | ! rowspan="22" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Atopic dermatitis]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Atopic dermatitis]] | ||
| | |Benign | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Epidermal barrier dysfunction | * Epidermal barrier dysfunction | ||
* [[Immune]] dysregulation | * [[Immune]] dysregulation | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 68: | Line 65: | ||
* [[Adolescent|Adolescents]] -flexural areas and buttock-thigh creases | * [[Adolescent|Adolescents]] -flexural areas and buttock-thigh creases | ||
* Adults - facial involvement and skin flexures | * Adults - facial involvement and skin flexures | ||
| | |||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 84: | Line 81: | ||
* White dermographism | * White dermographism | ||
* Perifollicular accentuation | * Perifollicular accentuation | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 95: | Line 89: | ||
* Psoriasiform [[hyperplasia]] | * Psoriasiform [[hyperplasia]] | ||
* Dyskeratosis | * Dyskeratosis | ||
| | |||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* | * | ||
Line 102: | Line 97: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref> | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref> | ||
| | |Benign | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Delayed-type [[hypersensitivity]] response | * Delayed-type [[hypersensitivity]] response | ||
* Skin [[inflammation]] mediated by [[Haptens|hapten]]-specific T cells | * Skin [[inflammation]] mediated by [[Haptens|hapten]]-specific T cells | ||
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure | | align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure | ||
| align="center" style="background:#F5F5F5;" | Erythematous well-demarcated [[papules]] | | align="center" style="background:#F5F5F5;" | Erythematous well-demarcated [[papules]] | ||
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent | | align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent | ||
| | |||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 119: | Line 112: | ||
* Localized [[swelling]] | * Localized [[swelling]] | ||
* [[Lichenification|Lichenified]] [[Itch|pruritic]] [[plaques]] | * [[Lichenification|Lichenified]] [[Itch|pruritic]] [[plaques]] | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 126: | Line 117: | ||
* [[Exocytosis]] of [[eosinophils]] and [[lymphocytes]] | * [[Exocytosis]] of [[eosinophils]] and [[lymphocytes]] | ||
* Chronic - [[Hyperkeratosis]] and parakeratosis | * Chronic - [[Hyperkeratosis]] and parakeratosis | ||
| | |||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Contact with [[allergens]] in the past 1-2 days | * Contact with [[allergens]] in the past 1-2 days | ||
Line 131: | Line 123: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref> | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref> | ||
| | |Benign | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Activation of the [[innate immune system]] by the pro-[[inflammatory]] properties of chemicals | * Activation of the [[innate immune system]] by the pro-[[inflammatory]] properties of chemicals | ||
| align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure | | align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure | ||
| align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface | | align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface | ||
| align="center" style="background:#F5F5F5;" | Any area in contact with the irritant | | align="center" style="background:#F5F5F5;" | Any area in contact with the irritant | ||
| | |||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 147: | Line 137: | ||
* Dryness | * Dryness | ||
* Thicker skin | * Thicker skin | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 153: | Line 142: | ||
* Intraepidermal [[vesicles]] or bullae | * Intraepidermal [[vesicles]] or bullae | ||
* [[Necrosis]] of [[keratinocytes]] | * [[Necrosis]] of [[keratinocytes]] | ||
| | |||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Cumulative exposure to [[irritants]] | * Cumulative exposure to [[irritants]] | ||
Line 158: | Line 148: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]] | ||
| | |Benign | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Keratinocyte]] hyperproliferation | * [[Keratinocyte]] hyperproliferation | ||
* Dysregulation of the [[immune system]] | * Dysregulation of the [[immune system]] | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | Well-circumscribed, pink [[papules]] and symmetrically distributed cutaneous [[plaques]] with silvery scales | | align="center" style="background:#F5F5F5;" | Well-circumscribed, pink [[papules]] and symmetrically distributed cutaneous [[plaques]] with silvery scales | ||
Line 171: | Line 159: | ||
* Gluteal cleft | * Gluteal cleft | ||
* Extensor surface of elbows and knees | * Extensor surface of elbows and knees | ||
| | |||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Auspitz's sign]] (pinpoint bleeding) | * [[Auspitz's sign]] (pinpoint bleeding) | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 183: | Line 170: | ||
* Parakeratosis | * Parakeratosis | ||
* [[Neutrophils]] microabscesses (Munro microabscesses) | * [[Neutrophils]] microabscesses (Munro microabscesses) | ||
| | |||
| colspan="2" align="center" style="background:#F5F5F5;" |Risk factors include | | colspan="2" align="center" style="background:#F5F5F5;" |Risk factors include | ||
* [[Smoking]] | * [[Smoking]] | ||
Line 192: | Line 180: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Eczema|Chronic eczema]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Eczema|Chronic eczema]] | ||
| | |Benign | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* | * | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | Scalp, face, trunk, postauricular, diaper area and axilla | | align="center" style="background:#F5F5F5;" | Scalp, face, trunk, postauricular, diaper area and axilla | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| | |||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
** | ** | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 211: | Line 196: | ||
* Psoriasiform [[hyperplasia]] | * Psoriasiform [[hyperplasia]] | ||
* [[Neutrophils]] at the margins | * [[Neutrophils]] at the margins | ||
| colspan=" | | colspan="3" align="center" style="background:#F5F5F5;" |Risk factors include | ||
* [[Stress]] | * [[Stress]] | ||
Line 221: | Line 206: | ||
! | ! | ||
! | ! | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
![[Bowen’s disease]] | |||
! | ! | ||
! | ! | ||
Line 236: | Line 235: | ||
! | ! | ||
|- | |- | ||
![[ | ![[Basal cell carcinoma|Superficial basal cell carcinoma]] | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
|- | |||
![[Basal cell carcinoma|Pagetoid basal cell carcinoma]] | |||
! | ! | ||
! | ! | ||
Line 254: | Line 267: | ||
! | ! | ||
|- | |- | ||
![[ | ![[Intraductal papilloma|Benign intraductal papilloma]] | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 260: | Line 282: | ||
! | ! | ||
! | ! | ||
|- | |||
!Pagetoid dyskeratosis | |||
! | ! | ||
! | ! | ||
Line 271: | Line 295: | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
|- | |||
![[Duct ectasia of breast|Lactiferous duct ectasia]] | |||
!Benign | |||
! | ! | ||
* Common among [[perimenopausal]]<nowiki/>women | |||
* Usually resolve spontaneously | |||
! | ! | ||
! | ! | ||
Line 290: | Line 317: | ||
! | ! | ||
|- | |- | ||
! | !Nipple duct adenoma | ||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 303: | Line 332: | ||
! | ! | ||
! | ! | ||
|- | |||
!Benign Toker cell hyperplasia | |||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
Line 319: | Line 348: | ||
! | ! | ||
! | ! | ||
|- | |||
![[Mastitis]] | |||
!Benign | |||
! | ! | ||
! | ! | ||
Line 325: | Line 357: | ||
! | ! | ||
! | ! | ||
! | ! | ||
!+ | |||
! | ! | ||
! | ! | ||
Line 333: | Line 364: | ||
! | ! | ||
! | ! | ||
|- | |||
![[Mondors disease]] | |||
! | ! | ||
! | ! | ||
Line 343: | Line 376: | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
|- | |||
![[Breast abscess]] | |||
!Benign | |||
! | ! | ||
! | ! | ||
Line 356: | Line 390: | ||
! | ! | ||
! | ! | ||
!+ | |||
! | ! | ||
! | ! |
Revision as of 22:00, 20 February 2019
Paget's disease of the breast Microchapters |
Differentiating Paget's disease of the breast from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Paget's disease of the breast differential diagnosis On the Web |
American Roentgen Ray Society Images of Paget's disease of the breast differential diagnosis |
Paget's disease of the breast differential diagnosis in the news |
Blogs on Paget's disease of the breast differential diagnosis |
Directions to Hospitals Treating Paget's disease of the breast |
Risk calculators and risk factors for Paget's disease of the breast differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]
Overview
Paget's disease of the breast must be differentiated from atopic dermatitis, eczema, psoriasis, malignant melanoma, Bowen's disease, basal cell carcinoma, and pagetoid dyskeratosis.[1][2]
Differential Diagnosis
Paget’s disease of the breast must be differentiated from other benign and malignant processes of nipple-areola complex such as:[1][2]
- Atopic dermatitis
- Chronic contact dermatitis
- Lactiferous duct ectasia
- Chronic eczema
- Psoriasis
- Nipple duct adenoma
- Malignant melanoma
- Bowen’s disease
- Superficial basal cell carcinoma
- Pagetoid basal cell carcinoma
- Benign intraductal papilloma
- Pagetoid dyskeratosis
Category | Diseases | Benign or Malignant | Etiology | Clinical manifestations | Para-clinical findings | Gold Standard | Associated factors | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||
Lab Findings | Histopathology | |||||||||||||||
Appearance | Itching | Mastalgia | Other | Serum IgE | ||||||||||||
Single/
Multiple |
Rash | Involved areas | Nipple
DIscharge |
Erythema | ||||||||||||
Skin disorders | Atopic dermatitis | Benign |
|
Multiple |
|
– | + | – |
|
↑ |
|
| ||||
Allergic contact dermatitis[3] | Benign |
|
May be multiple after 1-2 days of exposure | Erythematous well-demarcated papules | Surrounding the area in contact with the offending agent | – | + | + |
|
Nl |
|
| ||||
Irritant contact dermatitis[4] | Benign |
|
Usually single immediately after the exposure | Well-demarcated red patch with a glazed surface | Any area in contact with the irritant | – | + | + |
|
Nl |
|
| ||||
Psoriasis | Benign |
|
Multiple | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales |
|
+ | + | + |
|
Nl |
|
Risk factors include
| ||||
Chronic eczema | Benign |
|
Scalp, face, trunk, postauricular, diaper area and axilla | + | + | – |
|
Nl |
|
Risk factors include
Generalized seborrheic erythroderma in immunodeficient patients | ||||||
Malignant melanoma | ||||||||||||||||
Bowen’s disease | ||||||||||||||||
Superficial basal cell carcinoma | ||||||||||||||||
Pagetoid basal cell carcinoma | ||||||||||||||||
Benign intraductal papilloma | ||||||||||||||||
Pagetoid dyskeratosis | ||||||||||||||||
Lactiferous duct ectasia | Benign |
|
||||||||||||||
Nipple duct adenoma | ||||||||||||||||
Benign Toker cell hyperplasia | ||||||||||||||||
Mastitis | Benign | + | ||||||||||||||
Mondors disease | ||||||||||||||||
Breast abscess | Benign | + |
References
- ↑ 1.0 1.1 Gaspari, Eleonora; Ricci, Aurora; Liberto, Valeria; Scarano, Angela Lia; Fornari, Maria; Simonetti, Giovanni (2013). "An Unusual Case of Mammary Paget's Disease Diagnosed Using Dynamic Contrast-Enhanced MRI". Case Reports in Radiology. 2013: 1–5. doi:10.1155/2013/206235. ISSN 2090-6862.
- ↑ 2.0 2.1 Lopes Filho, Lauro Lourival; Lopes, Ione Maria Ribeiro Soares; Lopes, Lauro Rodolpho Soares; Enokihara, Milvia M. S. S.; Michalany, Alexandre Osores; Matsunaga, Nobuo (2015). "Mammary and extramammary Paget's disease". Anais Brasileiros de Dermatologia. 90 (2): 225–231. doi:10.1590/abd1806-4841.20153189. ISSN 1806-4841.
- ↑ Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
- ↑ Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.